1. P06 Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1–42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD. Issue 8 (August 2019) Authors: Grimmer, T.; Rabe, C.; Navarro, M.; Clayton, D.; Manuilova, E.; Peters, O.; Eichenlaub, U.; Smith, J.; Ostrowitzki, S.; Honigberg, L.; Bittner, T. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P32 Phase III studies of crenezumab in early (prodromal-to-mild) Alzheimers disease (CREAD/CREAD2): Biomarker results. Issue 4 (April 2020) Authors: Bittner, T.; Duning, T.; Rabe, C.; Clayton, D.; Quartino, A.; Bohorquez, S. Sanabria; Hu, N.; Rabbia, M.; Shimizu, H.; Eichenlaub, U.; Smith, J.; Honigberg, L.; Selkoe, D.J.; Ostrowitzki, S. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗